News

GlobalData on MSN2d
GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...
Pharmaceutical Technology8d
ATS 2025: GSK strengthens argument for twice-annual depemokimab
Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...
Pharmaceutical Technology8d
ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...
Pharmabiz2d
GSK seeks Health Canada approval for depemokimab to treat of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...
Yahoo Finance3d
GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...
The Globe and Mail3d
GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
MISSISSAUGA, ON, May 26, 2025 /CNW/ - GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance ...
I wasn't told my prostate pills would make me impotent. So many people are on them - shouldn't we be warned? DR SCURR's answer all men must read
I was prescribed the drugs tambulosin and finasteride for an enlarged prostate. But I was never warned that they might make ...